Last reviewed · How we verify
ExPEC10V
At a glance
| Generic name | ExPEC10V |
|---|---|
| Also known as | VAC52416 |
| Sponsor | Janssen Research & Development, LLC |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Study of Three Different Doses of VAC52416 (ExPEC10V) in Adults Aged 60 to 85 Years in Stable Health (PHASE1, PHASE2)
- Study to Collect Information About Invasive Disease Caused by Extraintestinal Pathogenic Escherichia Coli (EXPECT-1)
- A Study to Evaluate the Different Doses of VAC52416 (ExPEC10V) in Japanese Adults (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ExPEC10V CI brief — competitive landscape report
- ExPEC10V updates RSS · CI watch RSS
- Janssen Research & Development, LLC portfolio CI